Indian scientists develop more potent Anthrax vaccine

Aditi Jain New Delhi | Updated on June 17, 2019 Published on June 17, 2019

Anthrax is a deadly human disease caused by bacterium Bacillus anthracis that also infects animals like horses, sheep, cattle and goats.

A group of Indian scientists have developed a new vaccine against anthrax. It is claimed to be superior over existing vaccines as it can generate immune response to anthrax toxin as well as its spores rather than the toxin alone.

Anthrax is a deadly human disease caused by bacterium Bacillus anthracis that also infects animals like horses, sheep, cattle and goats. Humans, pigs and dogs are comparatively less susceptible and only get infected if exposed to copious amount of spores. In 2001, these spores were used as agents of bio-terrorism when letters containing anthrax spores were sent to some people in America, leading to widespread panic.

Spores of the bacterium that causes anthrax are present in soil and can stay in latent form for years. However, under favourable environmental conditions, they become active and start to infect. Often, animals pick up spores while grazing, following which spores germinate in their body and produce toxins.

The anti-anthrax vaccines available in market generate immune response against a Bacillus protein-protective antigen – a protein that helps in transport of bacillus toxins inside the cells. This means that immune response is triggered only when spores germinate in body and start producing bacterial proteins. Anyone vaccinated with such a vaccine would show no immune response to bacillus spores and only perform once spores germinate and release toxins.

Studies have, however, shown that when inactivated spores are injected in addition to vaccine, the protection towards bacillus is enhanced. Researchers from the Defence Research and Development Laboratory (DRDL), Mysore and Jawaharlal Nehru University (JNU) decided to develop a single vaccine which is effective against both the toxin and its spores so as to provide complete protection.

For this, they stitched together portions of two genes: protective antigen protein and protein present in outer layer of spore. The protein thus produced was fusion of the two proteins and was injected into mice. After few days, scientists found that injected mice had high concentration of antibodies against fused proteins in its blood, showing immune response against the injected protein. It was found that these antibodies were also able to individually bind both protective antigen and spore protein demonstrating that the vaccine can produce immune response against both spores and the toxin.

“The ability of fused protein to generate protective immune responses against both spores and toxin suggests it as an efficient vaccine candidate against B. anthracis infection,” explained Joseph Kingston, a scientist at DRDL, while speaking to India Science Wire.

While antibiotics are also available, vaccines for anthrax are necessary as the infection can cause death within 2-3 days leaving no scope for diagnosis and treatment.

While discussing the future directions, Rakesh Bhatnagar, co-author of the study and a professor at JNU, said, “We intend to study protective efficacy of this vaccine against Bacillus spores and toxins in higher animal models.”

The research team also included Saugata Majumder, Shreya Das, Shivakiran S. Makam from DRDL and Vikas Kumar Somani from JNU. The research results have been published in journal Frontiers in Immunology.

Twitter handle: @AditiJain1987

(India Science Wire)

Published on June 17, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.